-transparent.png){kind=logo}
Phenylacetate and phenylbutyrate, two novel inducers of tumor cytostasis and differentiation, are currently in clinical trials for the treatment of cancer in adults. The purpose of our study was to evaluate the plasma protein-binding characteristics of phenylacetate and phenylbutyrate in the plasma of normal volunteers and that of patients with cancer. Drug plasma protein-binding analysis was examined using three separate devices: a micropartition system and two equilibrium dialysis systems, all of which exhibited similar results. Phenylacetate and phenylbutyrate concentrations were determined by high-performance liquid chromatography. Both drugs exhibited concentration-dependent binding. Our results showed sodium phenylacetate to have a higher free fraction than sodium phenylbutyrate at corresponding concentrations (> 0.442 +/- 0.008 and > 0.188 +/- 0.001, respectively). Plasma pH did not greatly affect protein binding of either drug. As albumin concentration decreased, an increase in free fraction of both drugs was observed, however alpha 1-acid glyco-protein showed no change in free fraction as its concentration increased. Patients with cancer with lower levels of albumin showed an increase in free fraction with both phenylacetate and phenylbutyrate. When phenylacetate and phenylbutyrate were added together in plasma, the free fraction of phenylacetate increased, whereas the phenylbutyrate free fraction slightly decreased. We conclude that phenylacetate and phenylbutyrate have high free fractions that change with varying albumin levels and when both phenylacetate and phenylbutyrate are present together in plasma.
S Boudoulas, and
R M Lush, and
N A McCall, and
D Samid, and
E Reed, and
W D Figg
January 1997,
Advances in experimental medicine and biology,
S Boudoulas, and
R M Lush, and
N A McCall, and
D Samid, and
E Reed, and
W D Figg
April 1995,
Journal of clinical pharmacology,
S Boudoulas, and
R M Lush, and
N A McCall, and
D Samid, and
E Reed, and
W D Figg
January 2000,
Current oncology reports,
S Boudoulas, and
R M Lush, and
N A McCall, and
D Samid, and
E Reed, and
W D Figg
February 2000,
Clinical cancer research : an official journal of the American Association for Cancer Research,
S Boudoulas, and
R M Lush, and
N A McCall, and
D Samid, and
E Reed, and
W D Figg
March 2016,
Journal of pediatric gastroenterology and nutrition,
S Boudoulas, and
R M Lush, and
N A McCall, and
D Samid, and
E Reed, and
W D Figg
February 2004,
Clinical cancer research : an official journal of the American Association for Cancer Research,
S Boudoulas, and
R M Lush, and
N A McCall, and
D Samid, and
E Reed, and
W D Figg
October 2013,
Nihon yakurigaku zasshi. Folia pharmacologica Japonica,
S Boudoulas, and
R M Lush, and
N A McCall, and
D Samid, and
E Reed, and
W D Figg
May 2001,
Cancer chemotherapy and pharmacology,
S Boudoulas, and
R M Lush, and
N A McCall, and
D Samid, and
E Reed, and
W D Figg
October 1997,
Clinical cancer research : an official journal of the American Association for Cancer Research,
S Boudoulas, and
R M Lush, and
N A McCall, and
D Samid, and
E Reed, and
W D Figg
March 2006,
Annals of oncology : official journal of the European Society for Medical Oncology,
